venBio Partners LLC Long-Term Concentrated

CIK: 0001776382 · Show all filings

Period: Q4 2024 (← Previous) (Next →)

Filing Date: Feb 14, 2025

Total Value ($000): $170,706 (100.0% shares, 0.0% debt)

Holdings (7)

PHVS PHARVARIS N V 48.2%

Value ($000) $82,226 Shares 4,289,304 Est. Cost $21.15 Unrealized -2.7%

ALMS ALUMIS INC 12.8%

Value ($000) $21,909 Shares 2,787,398 Est. Cost $13.30 Unrealized -24.6%

HRMY HARMONY BIOSCIENCES HLDGS IN 10.9%

Value ($000) $18,554 Shares 539,194 Est. Cost $36.46 Unrealized -5.8%

ALXO ALX ONCOLOGY HLDGS INC 9.5%

Value ($000) $16,199 Shares 9,699,925 Est. Cost $39.31 Unrealized -96.1%

ARTV ARTIVA BIOTHERAPEUTICS INC 9.0%

Value ($000) $15,321 Shares 1,519,971 Est. Cost $11.59 Unrealized +3.6%

— ACELYRIN INC 7.0%

Value ($000) $11,952 Shares 3,806,410 Est. Cost $20.90 Unrealized —

— LYELL IMMUNOPHARMA INC 2.7%

Value ($000) $4,545 Shares 7,102,190 Est. Cost $0.64 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
PHVS	PHARVARIS N V	4,289,304	$82,226	48.2%	$21.15	-2.7%	COM	N69605108
ALMS	ALUMIS INC	2,787,398	$21,909	12.8%	$13.30	-24.6%	COM	022307102
HRMY	HARMONY BIOSCIENCES HLDGS IN	539,194	$18,554	10.9%	$36.46	-5.8%	COM	413197104
ALXO	ALX ONCOLOGY HLDGS INC	9,699,925	$16,199	9.5%	$39.31	-96.1%	COM	00166B105
ARTV	ARTIVA BIOTHERAPEUTICS INC	1,519,971	$15,321	9.0%	$11.59	+3.6%	COM	04317A107
—	ACELYRIN INC	3,806,410	$11,952	7.0%	$20.90	—	COM	00445A100
—	LYELL IMMUNOPHARMA INC	7,102,190	$4,545	2.7%	$0.64	—	COM	55083R104